KeyCorp Total Equity decreased by 1.9% to $19.99B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.2%, from $19.00B to $19.99B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 2.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase generally signals growth in retained earnings or capital injections, while a decrease may indicate share buybacks, dividend payments, or net losses.
This represents the residual interest in the assets of the entity after deducting all its liabilities. It reflects the n...
Standard across all public companies; peers in the medical device and diagnostics sector typically maintain high equity levels to support R&D and M&A.
total_stockholders_equity| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.94B | $17.51B | $17.42B | $15.31B | $14.43B | $13.29B | $13.45B | $14.32B | $13.84B | $13.36B | $14.64B | $14.55B | $14.79B | $16.85B | $18.18B | $19.00B | $19.48B | $20.10B | $20.38B | $19.99B |
| QoQ Change | — | -2.4% | -0.5% | -12.1% | -5.8% | -7.9% | +1.2% | +6.5% | -3.3% | -3.5% | +9.6% | -0.6% | +1.7% | +13.9% | +7.9% | +4.5% | +2.5% | +3.2% | +1.4% | -1.9% |
| YoY Change | — | — | — | — | -19.6% | -24.1% | -22.8% | -6.4% | -4.0% | +0.5% | +8.8% | +1.6% | +6.8% | +26.2% | +24.2% | +30.6% | +31.7% | +19.3% | +12.1% | +5.2% |